State Street’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.54M Buy
497,546
+49,682
+11% +$745K ﹤0.01% 2823
2025
Q4
$6.92M Buy
447,864
+40,025
+10% +$535K ﹤0.01% 2830
2025
Q3
$4.2M Buy
407,839
+39,102
+11% +$369K ﹤0.01% 3056
2025
Q2
$4.11M Buy
368,737
+196,882
+115% +$2.46M ﹤0.01% 3027
2025
Q1
$2.11M Buy
171,855
+23,552
+16% +$295K ﹤0.01% 3225
2024
Q4
$1.66M Sell
148,303
-7,187
-5% -$62.5K ﹤0.01% 3376
2024
Q3
$1.08M Buy
155,490
+12,912
+9% +$94.4K ﹤0.01% 3467
2024
Q2
$1.08M Buy
142,578
+105,327
+283% +$1.06M ﹤0.01% 3462
2024
Q1
$492K Buy
37,251
+3,900
+12% +$55.6K ﹤0.01% 3653
2023
Q4
$344K Buy
33,351
+100
+0.3% +$797 ﹤0.01% 3734
2023
Q3
$324K Buy
33,251
+10,800
+48% +$63.2K ﹤0.01% 3784
2023
Q2
$101K Hold
22,451
﹤0.01% 4236
2023
Q1
$104K Hold
22,451
﹤0.01% 4313
2022
Q4
$33.5K Hold
22,451
﹤0.01% 4645
2022
Q3
$84K Hold
22,451
﹤0.01% 4522
2022
Q2
$111K Sell
22,451
-76,266
-77% -$504K ﹤0.01% 4482
2022
Q1
$810K Buy
98,717
+2,042
+2% +$17.6K ﹤0.01% 3871
2021
Q4
$974K Sell
96,675
-930
-1% -$12.1K ﹤0.01% 3819
2021
Q3
$1.55M Buy
97,605
+24,799
+34% +$521K ﹤0.01% 3683
2021
Q2
$1.73M Buy
+72,806
New +$1.69M ﹤0.01% 3570

Other funds holding NPCE

State Street's NPCE Position: Q1 2026 in Review

State Street increased its Neuropace (NPCE) stake by 11% in Q1 2026, buying an estimated $745K and bringing the position to 497,546 shares worth $6.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2823.

State Street first reported a position in NPCE in Q2 2021 and has held it in 20 quarters since. The position peaked at $6.92M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • State Street held 497,546 shares of Neuropace worth $6.54M as of Q1 2026.
  • State Street bought 49,682 Neuropace shares in Q1 2026, an estimated $745K.
  • Neuropace made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2823 holding.
  • State Street first reported a position in Neuropace in Q2 2021 and has held it in 20 quarters since.
  • State Street's Neuropace position peaked at $6.92M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.